Mesoblast Ltd
MESO Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$12.39
KIRA · Stoqly’s AI analyst, in plain words
- Mesoblast Ltd had $120M of revenue in fiscal 2026, up 599.2% on the year before. Over five years, revenue changed +74.5% a year on average.
- Mesoblast Ltd lost $57.5M in fiscal 2026.
- Free cash flow was −$44.7M in fiscal 2026, −37.1% of revenue.
- Mesoblast Ltd owes $16.3M more than it holds in cash.
Market cap
$1.6B
P/E
—
Revenue
$120M
Net income
−$57.5M
Free cash flow
−$44.7M
Operating margin
—
Mesoblast Ltd in 30 seconds · fiscal 2026
Are sales growing?
+599.2%
Yes. Sales grew 599.2% last year.
Does it make a profit?
−47.8%
No. It lost money last year.
Does profit turn into cash?
−37.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Mesoblast Ltd does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 20-F · Aug 27, 2026
- Legal name
- MESOBLAST LTD
- CIK
- 0001345099
Mesoblast Ltd · MESO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $10.2M | $7.5M | $5.9M | $17.2M | $120M |
| Revenue growth | 37.4% | −26.5% | −21.3% | 191.4% | 599.2% |
| Gross margin | — | 100.0% | 100.0% | 70.2% | 86.1% |
| Net income | −$91.3M | −$81.9M | −$88.0M | −$102M | −$57.5M |
| Net margin | −894.6% | −1,091.7% | −1,490.3% | −593.9% | −47.8% |
| Diluted EPS | −$1.34 | −$1.05 | −$0.89 | −$0.85 | −$0.44 |
| Cash | |||||
| Cash from operations | −$65.8M | −$63.3M | −$48.5M | −$50.0M | −$43.8M |
| Capital expenditure | — | $0.3M | $0.3M | $0.7M | $0.8M |
| Free cash flow | — | −$63.5M | −$48.7M | −$50.6M | −$44.7M |
| FCF margin | — | −847.0% | −825.6% | −294.4% | −37.1% |
| Share count change | 12.9% | 13.9% | 26.9% | 22.4% | 7.2% |
| Debt and strength | |||||
| Cash and short-term investments | $60.4M | $71.3M | $63.0M | $162M | $103M |
| Debt incl. finance leases | $96.6M | $109M | $114M | $122M | $119M |
| Shareholders' equity | $497M | $502M | $480M | $597M | $568M |
| Current ratio | 1.4x | 1.9x | 1.2x | 2.0x | 2.4x |
| Returns and quality | |||||
| Return on equity | −16.9% | −16.4% | −17.9% | −19.0% | −9.9% |
| Return on tangible equity | −18.4% | −16.3% | −18.3% | −17.1% | −10.1% |
| Piotroski F-score | 2 | 3 | 1 | 5 | 6 |
Insiders bought, 12 months
$30.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Mesoblast Ltd · MESO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $12.39 a share, the company is worth $1.6B.
Source: SEC EDGAR XBRL filings (CIK 0001345099). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.